Leave R&D tax credits alone, warns Medicines Australia
This article was originally published in Scrip
Winding back Australia's R&D tax credit system could cause some companies to stop bringing R&D investment dollars to Australia, warned Dr Brendan Shaw, chief executive of Medicines Australia, in a statement today. His comments come in response to Australian media reports that the government may change the tax credit system in the forthcoming federal budget.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.